However, patients may notice changes in urination patterns indirectly related to improved blood glucose control, increased fluid intake to manage gastrointestinal symptoms, or concurrent medications
For patients with elevated inflammatory markers, addressing this pathway may reduce pain generation at its source
Fatigue and Headache: Some people may experience tiredness or headaches after starting these medications
[1] Because no GLP-1 patches are currently FDA-approved or commercially available , there is no established clinical protocol for their application
Until such evidence is available for retatrutide, therapies with established cardiovascular and renal benefitssuch as semaglutide, supported by SUSTAIN-6 [5] and FLOW [57] trials in people with T2D, and the SELECT trial [58] in people with obesity - should be prioritised in populations with existing cardio-renal disease